In a report released today, Corinne Jenkins from Goldman Sachs maintained a Buy rating on Roivant Sciences (ROIV – Research Report), with a price target of $12.00. The company’s shares closed last Tuesday at $3.81, close to its 52-week low of $2.52.
According to TipRanks.com, Jenkins is a 1-star analyst with an average return of -10.4% and a 50.0% success rate. Jenkins covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Rhythm Pharmaceuticals, and Bioxcel Therapeutics.
Roivant Sciences has an analyst consensus of Strong Buy, with a price target consensus of $11.67, a 203.9% upside from current levels. In a report issued on May 22, SVB Securities also initiated coverage with a Buy rating on the stock with a $6.00 price target.
The company has a one-year high of $16.76 and a one-year low of $2.52. Currently, Roivant Sciences has an average volume of 474.3K.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ROIV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Montes Archimedes Acquisition Corp is a blank check company.
Read More on ROIV: